Oxford Biomedica announced a new digital framework initiative to streamline the production of next-generation medicines. The company will invest £4m in total, $2m of which is allocated to support a grant from UK innovation agency Innovate UK.
The company claims the investment will help build its digital and robotics capabilities, as well as improve analytical methods, supply times and the cost of goods. The initiative is being undertaken to increase capacity, reduce manufacturing costs and reduce waste.
John Dawson, Oxford Biomedica’s CEO, commented: “This new initiative will provide us with digital and robotic enhancements to maintain our global leading position in the development and manufacture of lentiviral vector products. This is important for our own R&D pipeline as well as for our blue-chip partners as we continue to support the delivery of life-altering gene therapies to patients around the world.”